Novel checkpoint 1 inhibitors

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 1, 2006, Pages 55-68

  Prudhomme, Michelle ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Aminopyrazoles; Anticancer agents; Benzimidazole quinolines; Cell cycle; Chk1 inhibitors; Diarylurea derivatives; Diazepinoindole derivatives; G2 checkpoint

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; ENZYME INHIBITOR; PROTEIN KINASE;

ANIMAL; CHEMISTRY; DRUG EFFECT; GENE; HUMAN; NEOPLASM; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GENES, CDC; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745622302     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206775246520     Document Type: Review

References (53)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-39.
2. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-9.
3. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle:a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36: 131-49.
4. Cuddihy AR, O'Connell MJ. Cell-cycle responses to DNA damage. Internatl Rev Cytology 2003; 222: 99-140.
5. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents. Differential activity in cells expressing or not p53. Cell Cycle 2004; 3: 1177-81.
6. Chen Y, Sanchez Y. Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair 2004; 3:1025-32.
7. waf1 in normal and ATM-defective cells. Oncogene 2003; 22: 7866-9.
8. Xiao Z, Chen Z, Gunasekera AH, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNAdamaging agents. J Biol Chem 2003; 278: 21767-73.
9. McGowan CH. Running into problems: how cells cope with replicating damaged DNA. Mutation Res. 2003; 532: 75-84.
10. Anderson HJ, Andersen RJ, Roberge M. In: Meijer L, Jézéquel A, Roberge M. Eds, Progress in cell cycle research. Roscoff, "Life in progress" editions 2003; 5: 423-30.
11. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 4: 513-9.
12. Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002; 277: 46609-15.
13. Andersen, R. J., Roberge, M., Sanghera, J., Leung, D.: WO9947522A1 (1999).
14. Curman D, Cinel B, Williams DE, et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloïd debromohymenialdisine. J Biol Chem 2001; 276: 17914-19.
15. Syljuasen RG, Storgaard SC, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res 2004; 64: 9035-40.
16. Reich, S.H., Wallace, M.B.: US20020006952A1 (2002).
17. Chu, S. S, Alegria, L.A., Bender, S.L. et al.: US20020025976A1 (2002).
18. Booth, R.J., Denny, W.A., Dobrusin, E.M. et al.: WO03091255A1 (2003).
19. Lin, N.-H., Sham, H.L., Xia, P.: US20030162785A1 (2003).
20. Buhr, C.A., Baik, T.-G., Ma, S. et al.: WO03093297A2 and WO03093297A3 (2003).
21. Jacobs, R.S., Marshall, L.A., Gerwick, W.H., Stevenson, C.: US20020022589A1 (2002).
22. Chen P, Luo C, Deng Y, et al. The 1.7Å crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 2000; 100: 681-92.
23. Lyne PD, Kenny PW, Cosgrove DA, et al. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004; 47: 1962-68.
24. Johnson, M.D., Teng, M., Zhu, J.: WO05009435A1 (2005).
25. Dyckman, A.J., Das, J., Leftheris, K., Liu, C., Moquin, R.V., Wrobleski, S.T.: US20040248853A1 (2004).
26. Kephart, S.E., McAlpine, I.J., Reich, S.H.: US20050026960A1 (2005).
27. Kania, R.S., Bender, S.L., Borchardt, A.J. et al.: US20050124662A1 (2005).
28. Tong, Y., Claiborne, A.K., Li, G. et al.: US20040259904A1 (2004).
29. Benedict, S., Bennett, M., Ninkovic, S., Teng, M., Rui, Y., Wang, F.: US20050075499A1 (2005).
30. Ninkovic, S., Bennet, M.J., Rui, Y., Wang, F., Benedict, S.P., Teng, M.: WO04063198A1 (2004).
31. Anderes K, Blasina A, Castillo R, et al. Small molecule Chk1 inhibitor potentiates antitumor activity of chemotherapeutic agents in vivo. Proceedings of the American Association for Cancer Research 2005; 46: 1045.
32. Keegan, K.S., Kesicki, E.A., Gaudino, J.J., Cook, A.W., Cowen, S.C., Burgess, L.E.: US20030069284A1 (2003).
33. Boyle, R. G., Imogai, H.J., Cherry, M.: US20040014765A1 (2004).
34. Boyle, R. G., Imogai, H.J., Cherry, M. et al.: WO05028474A2 and WO05028474A3 (2005).
35. Li, G., Li, Q., Li, T. et al.:US20040259885A1 (2004).
36. Tao, Z.-F., Lin, N.-H., Wang, L., Sowin, T.J.: US20050096324A1 (2005).
37. Rui, E.Y., Johnson, T.O., Kellum J.H.: US20050148643A1 (2005).
38. Haswold, L.A., Hexamer, L., Li, G. et al.: US20040254159A1 (2004).
39. Bryant, J., Kochanny, M.J., Yuan, S. et al.: US20040186118A1 (2004).
40. Barsanti, P.A., Bussiere, D., Harrison, S.D. et al.: US20040092535A1 (2004).
41. Pevarello, P., Orsini, P., Traquandi, G. et al.: US20040019046A1 (2004).
42. Pao, T.-W., Fang, Y.-H.: US20050110741A1 (2004).
43. Berta, D.J., Forte, B., Mantegani, S., Varasi, M., Vianello, P.: US20050032869A1 (2005).
44. Cavicchioli, M., Pevarello, P., Salom, B., Vulpetti, A.: US20050059657A1 (2005).
45. Traquandi, G., Brasca, M.G., Orsini, P., Piutti, C., Vulpetti, A., Pevarello, P.: US20040116497A1 (2004).
46. Pevarello, P., Amici, R., Villa, M. et al.: US20040235919A1 (2004).
47. Bender, S., Skalitzky D.J., Hu-Lowe, D.: US20050038097A1 (2005).
48. Bhagwat, S.S., Satoh, Y., Sakata, S.T. et al.: US20050009876A1 (2005).
49. Amici, R., D'Anello, M., Martina, K., Salom, B., Vulpetti, A.: US20040254177A1 (2004).
50. Kawabe, T., Kobayashi, H.: US20040198727A1 (2004).
51. Pulici, M.: US20040020583A1 (2005).
52. Kawabe, T., Kobayashi, H.: US20040248783A1 (2004).
53. Prudhomme M. Combining DNA damaging agents and checkpoint 1 inhibitors. Curr Med Chem-Anti-Cancer Agents 2004; 4: 435-8.